Saphnelo approved in Japan for systemic lupus erythematosus

AstraZeneca

28 September 2021 - Saphnelo is a first in class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus.

AstraZeneca’s Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus, a serious auto-immune disease, who show insufficient response to currently available treatment.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Japan